Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 14/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | DRD4 | P21917 | 2/20 | 0.37 |
| ▸ | DRD3 | P35462 | 2/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30479043 | 1.00 | CRBN (0.49) | CRBNDDB1POLBGSPT1DRD2 | |
| SCHEMBL30955798 | 0.87 | CRBN (0.53) | CRBNDDB1POLBDRD2DRD3 | |
| SCHEMBL25034765 | 0.86 | CRBN (0.45) | CRBNDDB1POLBGSPT1 | |
| SCHEMBL30475488 | 0.86 | CRBN (0.45) | CRBNDDB1POLBGSPT1 | |
| SCHEMBL25031324 | 0.84 | CRBN (0.50) | CRBNDDB1POLB | |
| SCHEMBL30479072 | 0.84 | CRBN (0.50) | CRBNDDB1POLB | |
| SCHEMBL24670689 | 0.84 | CRBN (0.44) | CRBNDDB1POLBGSPT1 | |
| SCHEMBL27225017 | 0.81 | CRBN (0.44) | CRBNDDB1POLBDRD2DRD4 | |
| SCHEMBL30955788 | 0.80 | DDB1 (0.63) | CRBNDDB1 | |
| SCHEMBL24670181 | 0.79 | CRBN (0.43) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116261458-B | PLK1 degradation inducing compounds | 厄普特拉株式会社 | 2024-05-24 | — | — | CN | disclosed |
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-08-03 | — | — | US | disclosed |
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-08-03 | — | — | US | disclosed |
| CN-116261458-A | Novel PLK1 degradation inducing compounds | 厄普特拉株式会社 | 2023-06-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | CRBN 2136/4885DDB1 132/4885POLB 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.